INTRODUCTION {#s1}
============

Mitochondrial dysfunction leads to a diverse array of disorders most often characterized by myopathic and neurologic symptoms ([@MCS004309SCHC3]). As the mitochondria are essential for normal aerobic metabolism, tissues and organs with high energy demands such as skeletal muscle are particularly sensitive to mitochondrial disruption ([@MCS004309SCHC18]). Damaging variants in more than 1000 nuclear encoded and mitochondrial genes can affect respiratory chain complexes, mtDNA replication and maintenance, and dynamic fusion and fission processes. Fusion helps maintain a healthy population of mitochondria by distributing mtDNA and metabolites and eliminating damaged mitochondria through mitophagy (for review, see [@MCS004309SCHC4]).

*MSTO1* (Misato 1) is a nuclear gene that contains a region homologous to the Tubulin/FtsZ, GTPase superfamily, which contains proteins that regulate chromosome segregation in eukaryotes and mitochondrial fission in eukaryotic algae ([@MCS004309SCHC9]). It encodes a soluble cytoplasmic protein that translocates to the mitochondrial outer membrane and promotes normal fusion dynamics ([@MCS004309SCHC9]; [@MCS004309SCHC5]; [@MCS004309SCHC15]; [@MCS004309SCHC4]). In *Drosophila*, knockdown of *DML1*, the homolog of human *MSTO1*, leads to defects in chromosome segregation during mitosis ([@MCS004309SCHC14]). In *Saccharomyces cerevisiae*, disruption of *DML1* causes impaired inheritance of mtDNA and segregation of mitochondria ([@MCS004309SCHC6]). Inhibition of *MSTO1* in HeLa cells results in nuclear and mitochondrial fragmentation, reduced fusion, and apoptosis, whereas overexpression results in perinuclear aggregations of mitochondria ([@MCS004309SCHC9]; [@MCS004309SCHC5]).

*MSTO1* was first associated with human disease in 2017 when Nasca et al. reported on three patients with compound heterozygous variants in *MSTO1* presenting with myopathy and cerebellar ataxia (MIM:617675). Functional studies in patient fibroblasts confirmed partially reduced transcript and protein expression as well as fragmentation of the mitochondrial network and decreased mitochondrial fusion ([@MCS004309SCHC15]). To date, a total of 11 patients have been reported in the literature with myopathy and ataxia attributed to pathogenic variants in *MSTO1*. Consistent phenotypic features observed across patients include onset in the first year of life, severe motor delay, cerebral atrophy on MRI, short stature, myopathic pattern on EMG, and elevated plasma creatine kinase (CK) ([Table 1](#MCS004309SCHTB1){ref-type="table"}; [@MCS004309SCHC15]; [@MCS004309SCHC7]; [@MCS004309SCHC11]). Additionally, several patients presented with cognitive deficiencies, skeletal abnormalities, tremors, and retinopathy.

###### 

Phenotypic spectrum of *MSTO1*-associated myopathy

                                [@MCS004309SCHC15]; Patient 1                                           [@MCS004309SCHC15]; Patient 2   [@MCS004309SCHC15]; Patient 3                  [@MCS004309SCHC7]; Patient 1                                                     [@MCS004309SCHC7]; Patient 2         [@MCS004309SCHC11]; Patient 1         [@MCS004309SCHC11]; Patient 2     Present study                                                [@MCS004309SCHC5]; Patient 1                                                [@MCS004309SCHC5]; Patient 2                               [@MCS004309SCHC5]; Patient 3                                    [@MCS004309SCHC5]; Patient 4
  ----------------------------- ----------------------------------------------------------------------- ------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------ ------------------------------------- --------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------- ------------------------------
  Variant 1 (cDNA)              c.1033C \> T                                                            c.1033C \> T                    c.971C \> T                                    c.836 G \> A                                                                     c.836 G \> A                         c.836G \> A                           c.836G \> A                       c.651 C\>G                                                   c.22G \> A                                                                  c.22G \> A                                                 c.22G \> A                                                      c.22G \> A
  Variant 1 (protein)           p.R345C                                                                 p.R345C                         p.T324I                                        p.Arg279His                                                                      p.Arg279His                          p.Arg279His                           p.Arg279His                       p.F217L                                                      p.Val8Met                                                                   p.Val8Met                                                  p.Val8Met                                                       p.Val8Met
  Variant 2 (cDNA)              c.1128C \> A                                                            c.1128C \> A                    966+1G\>A                                      c.1099--1 G \> A                                                                 c\. 79 C\>T                          c.1259DelG                            c.1259DelG                        1q22 125 kb deletion                                         None                                                                        None                                                       None                                                            None
  Variant 2 (protein)           p.F376L                                                                 p.F376L                         n/a (splice)                                   p.Val367Trpfs \*2                                                                p.Gln27\*                            p.Gly420ValfsTer2                     p.Gly420ValfsTer2                 n/a                                                          None                                                                        None                                                       None                                                            None
  Variant 1 Type                Missense                                                                Missense                        Missense                                       Missense                                                                         Missense                             Missense                              Missense                          Missense                                                     Missense                                                                    Missense                                                   Missense                                                        Missense
  Variant 2 Type                Missense                                                                Missense                        Splice site                                    Splice site                                                                      Nonsense                             Frameshift                            Frameshift                        Partial gene deletion                                                                                                                                                                                                                                               
  Inheritance                   AR                                                                      AR                              AR                                             AR                                                                               AR                                   AR                                    AR                                AR                                                           AD                                                                          AD                                                         AD                                                              AD
  Age of onset                  8--9 mo                                                                 8--9 mo                         1 yr                                           5 mo                                                                             Perinatal                            1 yr                                  10 mo                             Perinatal                                                    53 yr                                                                       15 yr                                                      Childhood onset                                                 Early childhood
  Motor delay?                  Yes                                                                     Yes                             Yes                                            Yes                                                                              Yes                                  Yes                                   Yes                               Yes                                                          Yes                                                                         No                                                         No                                                              Yes
  Brain MRI                     Cerebellar atrophy                                                      Cerebellar atrophy              Cerebellar atrophy                             Cerebellar atrophy                                                               Cerebellar atrophy                   Cerebellar atrophy                    Cerebellar atrophy                n/a                                                          Frontal atrophy and enlarged interhemispheric fissure                       Pituitary adenoma and mild cerebellar ectopia              n/a                                                             n/a
  Growth impairment             Yes                                                                     Yes                             n/a                                            Yes                                                                              Yes                                  Yes                                   Yes                               No                                                           Yes                                                                         n/a                                                        n/a                                                             n/a
  Plasma CK value               1200                                                                    1872                            4520                                           430                                                                              916                                  n/a                                   2544                              1292                                                         Normal                                                                      Normal                                                     Normal                                                          n/a
  Tremors                       Yes                                                                     Yes                             Yes                                            Yes                                                                              Yes                                  No                                    No                                No                                                           No                                                                          No                                                         No                                                              No
  Cognitive deficiency          None                                                                    None                            Speech delay, speech articulation difficulty   Mild developmental delay                                                         Mild developmental delay             Developmental delay, slurred speech   Mental retardation                Learning disability, speech difficulty                       Developmental delay                                                         None                                                       Learning difficulties                                           Learning difficulties
  Ophthalmological findings     Pigmentary retinopathy with papillary pallor                            Bilateral papillary pallor      Normal                                         Bilateral retinal pigmentary denaturation, severe hypermetropia, and esotropia   Pigmentary retinal denaturation      Visual impairment                     Myopia                            No                                                           No                                                                          No                                                         No                                                              No
  Skeletal abnormalities        Severe asymmetry of the chest, pectus excavatum, and marked scoliosis   Asymmetry of the thorax         None                                           None                                                                             Multiple arthrogryposis, transient   Pes planus                            Pes planus and mild genu valgus   Pectus excavatum, reversal of cervical lordosis, scoliosis   III digit on foot missing, bone age delayed, joint hyperlaxity, pes varus   None                                                       Bone developmental problems, pectus excavatum, kyphoscoliosis   Laxity of the knee joints
  Walking affected?             Unable to walk                                                          Unable to walk                  Able to walk but occasional falls              Walked at 4 yr but loss at 13 yr                                                 No walking as of 3 yr                Able to walk                          Able to walk                      Waddling gait                                                Able to walk                                                                Severe episodic ataxic gait repeatedly                     Able to walk                                                    Able to walk
  Muscle biopsy abnormalities   Yes                                                                     Yes                             Yes                                            n/a                                                                              n/a                                  n/a                                   n/a                               n/a                                                          Yes                                                                         n/a                                                        n/a                                                             n/a
  EMG findings                  Myopathic pattern                                                       Myopathic pattern               Myopathic pattern                              n/a                                                                              n/a                                  n/a                                   Myopathic pattern                 Myopathic pattern                                            Myopathic pattern                                                           n/a                                                        n/a                                                             n/a
  Neurological disorders        None                                                                    None                            None                                           None                                                                             None                                 Autism, anxiety                       None                              Autism                                                       Hypoacusis, anxiety and depressed mood                                      Depression, hallucinations, schizophrenia, hypoacusis      Social anxiety                                                  Social anxiety, autism
  Respiratory symptoms          None                                                                    None                            None                                           None                                                                             None                                 None                                  None                              Yes                                                          None                                                                        None                                                       None                                                            None
  Other                         None                                                                    None                            None                                           None                                                                             None                                 None                                  None                              Dysphagia, restrictive lung disease                          Lipomatosis, hyperthyroidism, mitral and trisucpidal insufficiency          Inflammatory lipomas, Hyperthyreosis, hyperprolactanemia   None                                                            None

Comparisons of variants, inheritance, and phenotypic features seen across all currently reported patients with *MSTO1*-associated mitochondrial myopathy. n/a, Not available.

Here we present a 30-yr-old male with phenotypic features consistent with previously reported *MSTO1* patients. We report additional phenotypic features seen in our patient including dysphagia and restrictive lung disease, which may be the consequence of the associated myopathy. Our patient has a novel partial gene deletion adding to the spectrum of variants associated with *MSTO1*-associated mitochondrial myopathy.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A 30-yr-old Caucasian male presented with moderate-to-severe proximal and distal muscle weakness and significantly decreased muscle tone. He had congenital hypotonia with poor head control and was diagnosed with "muscular dystrophy of unknown type" at 18 mo of age. His gross and fine motor milestones were significantly delayed, including walking at 26 mo of age and the inability to pedal a bike or run as a child. Learning disability was noted at early childhood. Neurological examination at age 30 was significant for proximal and distal muscle weakness with hypotonia, mild facial weakness with ptosis, diminished muscle bulk, no sensory deficits, and preserved muscle reflexes. Gait was wide based and waddling. Swallowing video fluoroscopy revealed mild oropharyngeal dysphagia. Electromyogram (EMG) results were consistent with a longstanding, generalized myopathy, with electrodiagnostic features that would predict fiber splitting, necrosis, inflammation, or vacuolar change. He has persistently elevated CK levels with titers between 1000 and 2000 U/L. Pulmonary function tests showed a chronic restrictive pattern with forced vital capacity (FVC) at 44%--49% of predicted leading to a diagnosis of restrictive lung disease ([Fig. 1](#MCS004309SCHF1){ref-type="fig"}A,B).

![Pulmonary function and skeletal abnormalities in a patient with biallelelic *MSTO1* variants. (*A*) Airflow (L/sec) versus volume (L) displays a severe restriction of pulmonary function. (*B*) The forced expiratory volume in 1 sec (FEV1)/FVC is normal; the FEV1 is moderately to severely reduced; the FVC is reduced; maximal expiratory pressure (MEP) 24% predicted, maximal inspiratory pressure (MIP) 38% predicted. Overall results of the pulmonary function test confirm a chronic restrictive pattern. Skeletal radiographs (*C*) show mild reversal of cervical lordosis and (*D*) trace gentle convex curvature of the lumbar spine to the right.](MCS004309Sch_F1){#MCS004309SCHF1}

Additional phenotypic features reported in the patient include pectus excavatum that was surgically corrected at age 18, as well as scoliosis characterized by mild reversal of cervical lordosis and a trace gentle convex curvature of the lumbar spine to the right ([Fig. 1](#MCS004309SCHF1){ref-type="fig"}C,D). An echocardiogram was normal. The family history was unremarkable with the exception of a maternal grandmother who died of complication from ALS at age 74 ([Fig. 2](#MCS004309SCHF2){ref-type="fig"}).

![Family pedigree. A three-generation family pedigree in which the proband is the only affected individual. Each *MSTO1* variant was inherited from an unaffected parent.](MCS004309Sch_F2){#MCS004309SCHF2}

Genomic Analysis {#s2b}
----------------

Initial genetic testing included a 141-gene panel (Neuromuscular Genetics Panel; Mayo Clinic) and dystrophin deletion/duplication sequencing analysis. None of the variants reported were considered relevant ([Table 2](#MCS004309SCHTB2){ref-type="table"}). Testing for Pompe disease was also negative. Mitochondrial DNA NGS testing was performed through GeneDx, and a homoplasmic variant of uncertain significance (m.8045A\>G, p.I154V) was reported in *MT-CO2*. This variant was also considered not diagnostic as the patient\'s unaffected mother was homoplasmic for the same variant. Whole-exome sequencing performed through GeneDx reported two potentially clinically relevant variants; a maternally inherited NM_018116.3:c.651C\>G, p.F217L missense variant of uncertain significance and a likely pathogenic paternally inherited arr\[GRCh37\] 1q22(155581773_155706887) × 1 copy-number change ([Table 3](#MCS004309SCHTB3){ref-type="table"}; [Fig. 3](#MCS004309SCHF3){ref-type="fig"}A). The copy-number change was originally detected through GeneDx\'s NGS--CNV caller ([@MCS004309SCHC16]) and was confirmed by GeneDx with the GenomeDx v5 chromosomal array. The missense variant was confirmed by GeneDx via direct gene-specific PCR.

![Gene location of disease-associated *MSTO1* variants. (*A*) Map of currently known variants associated with mitochondrial myopathy. Green and blue regions denote the tubulin domains. Most of the variants cluster in the known tubulin domains. Figure generated using ProteinPaint, St. Jude Children\'s Research Hospital. (*B*) The amino acid affected by our patient\'s missense variant (red box) shows high conservation among orthologs.](MCS004309Sch_F3){#MCS004309SCHF3}

###### 

Discarded variants of uncertain significance

  Gene       Chromosome    HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect   dbSNP/dbVAR ID   Genotype       Reason discarded
  ---------- ------------- -------------------- ------------------------ -------------- ------------------ ---------------- -------------- -------------------------------------------------------------------------------------------------
  *CAVIN1*   17:40556955   c.923A\>G            p.Y308C                  Missense       Substitution       rs146799286      Heterozygous   Lack of phenotypic overlap (no lipodystrophy); no second variant found
  *SMCHD1*   18:2732423    c.3209T\>C           p.I1070T                 Missense       Substitution       rs113434340      Heterozygous   Lack of phenotypic overlap; no second variant found in DUX4
  *TMEM43*   3:14177385    c.859C\>T            p.H287Y                  Missense       Substitution       rs780299346      Heterozygous   Lack of phenotypic overlap (no cardiovascular symptoms)
  *TTN*      2:179419690   c.80792T\>G          p.L26931R                Missense       Substitution       rs72648234       Heterozygous   Autosomal dominant association with disease but previously reported in unaffected individuals
  *TTN*      2:179587094   c.18688G\>A          p.A6230T                 Missense       Substitution       rs759713604      Heterozygous   Autosomal dominant association with a disease but previously reported in unaffected individuals

Prior to whole-exome sequencing, a 141-gene Neuromuscular Genetics Panel was performed on patient DNA. Several variants of uncertain significance were reported, but all were discarded as candidates for the reasons described in the table.

###### 

Variant table

  Gene      Chromosome    HGVS DNA reference                HGVS protein reference   Variant type         Predicted effect        dbSNP/dbVAR ID   Genotype       Parent of origin
  --------- ------------- --------------------------------- ------------------------ -------------------- ----------------------- ---------------- -------------- ------------------
  *MSTO1*   1:155581864   c.651C\>G                         p.Phe217Leu              Missense             Substitution            rs776826330      Heterozygous   Mother
  *MSTO1*   1q22          1q22(155581773\_ 155706887) × 1   n/a                      Copy-number change   Partial gene deletion   n/a              Heterozygous   Father

The p.F217L missense variant lies in exon 7 of 14 in the tubulin domain. The affected amino acid is highly conserved across species ([Fig. 3](#MCS004309SCHF3){ref-type="fig"}B), and in silico predictions agree the variant is likely damaging (PolyPhen-2 \[[@MCS004309SCHC1]\], SIFT \[[@MCS004309SCHC17]\], M-CAP \[[@MCS004309SCHC8]\], and PredictSNP2 \[[@MCS004309SCHC2]\]). The p.F217L variant could possibly affect the structural conformation as it is a part of an α-helix and the only hydrophobic residue within a region of charged and hydrophilic residues. The 1q22(155581773_155706887 × 1) copy-number variant is a 125-kb deletion encompassing exons 7--14 of *MSTO1*, exon 7--13 of the *MSTO2P* pseudogene, and all of *DAP3* (death-associated protein 3) and *YY1AP1* (YY1 associated protein 1). Although the homology between *MSTO1* and its pseudogene could affect the detection of CNVs in this gene, the fact that the missense variant in exon 7 was called as homozygous supports the presence of a deletion in this gene. *MSTO2P* is not associated with any human disorders other than potential links to cancer, which are not reported in our patient. Biallelic loss of function variants in *YY1AP1* are associated with Grange syndrome, whereas missense and small insertion variants in *DAP3* have been associated with metabolic disorders and autism spectrum disorder. Because our patient does not have a second damaging variant reported in these genes and his phenotype does not overlap with these syndromes, we concluded that it is not likely that a single-copy loss of any of these three genes is contributing to our patient\'s phenotype.

*MSTO1* is not predicted to be intolerant to loss of function or missense variation based on gene constraints in gnomAD (pLI = 0, *Z* = 0) ([@MCS004309SCHC10]). However, as autosomal recessive inheritance is expected, it is possible to see damaging variants in a heterozygous state in the normal population. The p.F217L variant is observed at a very low frequency in gnomAD (0.007%) with no homozygotes reported. This variant has not been previously reported in HGMD or ClinVar. The 1q22(155581773_155706887) deletion has not been previously observed in normal or diseased individuals. Based on the Database of Genomic Variants, similarly sized deletions have been detected in heterozygotes in the normal population (nsv436522, nsv3043, nsv48213) ([@MCS004309SCHC12]).

DISCUSSION {#s3}
==========

Here we present a patient with novel compound heterozygous variants in *MSTO1* and mitochondrial myopathy. His phenotypic presentation overlaps well with previously reported patients including early-onset muscle weakness, motor delay, elevated plasma CK, myopathic pattern on EMG, and skeletal abnormalities. At 30 years old, our patient is the oldest reported patient with biallelic variants in *MSTO1*, adding important knowledge about potential life span for other similarly affected patients. We report features including restrictive lung disease and dysphagia not previously identified in patients with *MSTO1*-associated mitochondrial myopathy. These additional clinical findings may be the consequence of the associated myopathy. Awareness of the full phenotypic spectrum associated with this disorder is critical for proper diagnosis of future patients. As the role of tubulins in mitochondrial function becomes more apparent ([@MCS004309SCHC13]), it will be important to elucidate the role of MSTO1 in normal mitochondrial dynamics and how disruption leads to myopathy as well as skeletal, retinal, and other phenotypic features observed.

The p.F217L missense variant seen in our patient lies in the second tubulin domain on the MSTO1 protein. Five of the six previously reported pathogenic missense variants lie in one of the tubulin domains, suggesting these regions are critical for normal protein function and/or stability. Regions of proteins that bind to other proteins often have a hydrophobic center with a hydrophilic and charged ring surrounding them, much like the region around p.F217. If protein interactions with the MSTO1 tubulin domain occur at p.F217, then p.L217 may be compatible with the overall pattern of protein interfaces, but with a reduced and smaller hydrophobic center, which may not be as specific for its binding partners.

Similar to our patient, five of the 11 previously reported patients were compound heterozygotes with one missense variant and one loss-of-function variant ([Fig. 3](#MCS004309SCHF3){ref-type="fig"}A). The two most severely affected patients were compound heterozygotes for two missense variants. [@MCS004309SCHC15] hypothesized that the reduction in protein expression in these patients was due to instability caused by the missense variants. In the gnomAD database of healthy individuals, there is only one individual reported as homozygous for any loss of function allele and this call was flagged as dubious. This suggests that *MSTO1* is associated with disease in an autosomal recessive manner wherein biallelic loss of function variants are likely lethal but retention of a partially functional missense allele in conjunction with a loss of function allele results in a disease state. This is supported by studies in *Drosophila* in which null mutations are embryonic lethal ([@MCS004309SCHC14]). Here we present an additional patient with a loss-of-function variant, in this case a partial gene deletion, in combination with a missense variant in *MSTO1* resulting in mitochondrial myopathy.

Contrary to the other reported cases, Gal et al. reported a heterozygous missense variant in members of a family presenting with myopathy, ataxia, and neurodevelopmental impairments ([@MCS004309SCHC5]). A second alteration in *MSTO1* was not detected with Sanger sequencing of the genomic DNA or real-time PCR analysis of copy-number variation. The authors proposed autosomal dominant inheritance of a multisystemic clinical phenotype. However, the phenotypic features in this family do not overlap well with other reported patients ([Table 1](#MCS004309SCHTB1){ref-type="table"}). In particular, the age of onset was later (15--53 yr old), plasma CK levels were normal, and cerebellar atrophy was not observed. Functional studies in fibroblasts from patients 1 and 2 (as labeled in the Gal et al. study) did confirm a decrease in transcript and protein expression, mitochondrial fusion, and fragmented and aggregated mitochondria. These discrepant reports may be explained by a genotype/phenotype correlation in which the mode of inheritance depends on the location of the variant or a separate underlying genetic condition.

This case adds to our current knowledge on mitochondrial myopathy associated with biallelic pathogenic variants in *MSTO1.* We present novel phenotypic features not previously described in association with *MSTO1*-related disease and add support to reports of autosomal recessive inheritance. We expect that additional *MSTO1* cases and further research will elucidate the full clinical spectrum of this disorder.

METHODS {#s4}
=======

Whole-exome sequencing was performed by GeneDx. The mean depth of coverage was 157× and the quality threshold (percentage of sequence covered by at least 10 reads) was 98.9%. Briefly, a proprietary capture system was used for next-generation sequencing and targets were sequenced with paired-end reads on an Illumina platform. Reads were aligned to GRCH37/UCSC hg 19. Sequence variants and deletions or duplications involving three or more coding exons were called with XomeAnalyzer. Variants were reported according to the Human Genome Variation Society (HGVS) guidelines. Missense variants were clinically confirmed with direct gene-specific PCR. Copy-number variants were clinically confirmed by chromosomal microarray. Briefly, the GeneDx GenomeDx v5 chromosomal array contains 118,000 oligonucleotide probes and 66,000 SNP probes throughout the genome used for detecting copy-number variants.

The sequencing coverage was as follows: mean depth of coverage was 157× and the quality threshold was 98.9%.

As a separate test from whole-exome sequencing, mitochondrial sequencing and deletion testing of the mitochondrial genome were performed by GeneDx. Briefly, the mitochondrial genome was amplified and sequenced using a solid state sequencing-by-synthesis process and the sequence was compared to the revised Cambridge Reference Sequence (rCRS). Disease-associated variants were confirmed by conventional dideoxy sequence analysis.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Single-nucleotide variants identified and interpreted by GeneDx can be found in the ClinVar database (<https://www.ncbi.nih.nlm.gov/clinvar/>) under accession number SCV000965685. Patient permission was not granted for raw sequencing data deposition.
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